PDAC

This study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…

This program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This study tests two experimental drugs, IN10018 and RNK08954, together in people with advanced solid tumors that have a specific KRASG12D mutation. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or metastatic…

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has specific genetic changes (MTAP loss and, in some cases, a RAS mutation). The goal is to find safe doses and see if the combinations shrink tu…

This phase 3 study tests a new drug called daraxonrasib, either alone or with standard chemotherapy, in people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps patients live longer or slows tumor growth. About 900 adults with a specific …

This study tests whether adding an experimental drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) helps people with advanced pancreatic cancer live longer or shrink their tumors. About 900 adults with pancreatic cancer that has spread will be randomly assigne…

This study tests a new drug called RMC-5127, alone or with other medicines, in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific KRAS G12V mutation. The goal is to see if the drug is safe and can shrink tumors. About 574 particip…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemo alone. The goal is t…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This study is testing whether adding simple blood tests and symptom reviews to standard screening can find pancreatic cancer earlier in people with a high genetic risk. About 5,000 participants with certain gene changes will be followed over time. The goal is to catch cancer at a…

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…